Industry
Biotechnology
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Loading...
Open
17.83
Mkt cap
1.4B
Volume
1.5M
High
17.99
P/E Ratio
-4.13
52-wk high
27.20
Low
17.25
Div yield
N/A
52-wk low
11.40
Portfolio Pulse from
November 12, 2024 | 2:45 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 1:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Insights
September 26, 2024 | 6:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 5:57 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 2:11 pm
Portfolio Pulse from Benzinga Newsdesk
September 13, 2024 | 1:54 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 5:43 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 3:45 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.